<DOC>
	<DOCNO>NCT01413828</DOCNO>
	<brief_summary>Most publish data support preferential use anthracycline-containing adjuvant regimen individual HER2-positive tumor . Concurrent anthracyclines trastuzumab , however , contraindicate due observation unacceptably high rate cardiotoxicity large randomize trial metastatic setting . However , neoadjuvant setting , trastuzumab concurrently anthracycline-containing chemotherapy regimen show high pathological complete response ( pCR ) low cardiotoxicity . All large adjuvant trial evaluate sequential strategy administer anthracyclines trastuzumab . The safety efficacy trastuzumab concurrently anthracycline-containing chemotherapy regimen never evaluate adjuvant setting . Given similar patient characteristic , investigator hypothesize trastuzumab concurrently anthracycline-containing chemotherapy regimen would increase cardiotoxicity efficacy .</brief_summary>
	<brief_title>Trastuzumab Administered Concurrently Sequentially Anthracycline-containing Adjuvant Regimen Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Written inform consent . Histological diagnosis operable invasive adenocarcinoma breast . Tumours must HER2 positive . Time window surgery study randomization must less 60 day . Surgery must consist mastectomy conservative surgery axillary lymph node dissection sentinel lymph node biopsy . Margins free disease ductal carcinoma situ ( DCIS ) require . Lobular carcinoma consider positive margin . Positive axillary lymph node define least 1 10 node presence disease . If sentinel node technique use , sentinel node node affect . Status hormone receptor primary tumour must available end adjuvant chemotherapy . Patients must present evidence metastatic disease . Status HER2 primary tumour , know randomization . Patients immune histochemistry ( IHC ) 3+ eligible . For patient ICH 2+ , fluorescence situ hybridization ( FISH ) mandatory result must positive . Age &gt; = 18 &lt; = 70 year old . Performance status ( Karnofsky index ) &gt; = 80 . Normal electrocardiogram ( EKG ) 12 week prior randomization . Cardiac function monitor leave ventricular ejection fraction ( LVEF ) must &gt; = 55 % . Laboratory result ( within 14 day prior randomization ) : Hematology : neutrophil &gt; = 1.5 x 10^9/l ; platelet &gt; = 100 x 10^9/l ; hemoglobin &gt; = 10 mg/dl ; Hepatic function : total bilirubin &lt; = 1 upper normal limit ( UNL ) ; SGOT SGPT &lt; = 2.5 UNL ; alkaline phosphatase &lt; = 2.5 UNL . If value SGOT SGPT &gt; 1.5 UNL associate alkaline phosphatase &gt; 2.5 UNL , patient eligible ; Renal function : creatinine &lt; = 175 mmol/l ( 2 mg/dl ) ; creatinine clearance &gt; = 60 ml/min ; Complete stage workup 12 week prior randomization ( mammogram allow within 20 week window ) . All patient must bilateral mammogram , thorax xray , abdominal echography and/or compute tomography ( CT ) scan . If bone pain , and/or alkaline phosphatase elevation , bone scintigraphy mandatory . This test recommend patient . Other test : clinically indicate . Patients able comply treatment study followup . Negative pregnancy test do 14 prior day randomization . Prior systemic therapy breast cancer . Prior therapy anthracyclines trastuzumab malignancy . Prior radiotherapy breast cancer . Bilateral invasive breast cancer . Pregnant lactating woman . Adequate contraceptive method must use chemotherapy hormone therapy treatment . Any M1 tumor . HER2 negative breast cancer ( IHC 0or 1+ negative FISH result ) . Preexisting grade &gt; = 2 motor sensorial neurotoxicity ( National Cancer Institute Common Toxicity Criteria version 2.0 [ NCI CTC v2.0 ] ) . Any serious medical pathology , congestive heart failure ; unstable angina ; history myocardial infarction previous year ; uncontrolled HA high risk arrhythmia . leave ventricular ejection fraction ( LVEF ) less 55 % . History neurological psychiatric disorder , could preclude patient free informed consent . Active uncontrolled infection . Active peptic ulcer ; unstable diabetes mellitus . Previous current history neoplasms different breast cancer , except skin carcinoma , cervical situ carcinoma , tumour curatively treat without recurrence last 10 year ; ductal situ carcinoma breast ; lobular situ carcinoma . Chronic treatment corticosteroid . Contraindications corticosteroid administration . Concomitant treatment raloxifene , tamoxifen selective estrogen receptor modulators ( SERMs ) , either osteoporosis treatment prevention . These treatment must stop randomisation . Concomitant treatment investigational product ; participation clinical trial nonmarketed drug 20 previous day randomization . Concomitant treatment another therapy cancer . Males .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>breast cancer</keyword>
	<keyword>adjuvant chemotherapy</keyword>
	<keyword>trastuzumab</keyword>
	<keyword>anthracycline</keyword>
</DOC>